Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals Licenses from Myriad Suite of Cancer-Risk Proteins and Antibodies

NEW YORK, Jan. 15 (GenomeWeb News) - Serologicals' Chemicon International division has licensed certain tumor suppressor and breast cancer proteins and antibodies made by Myriad Genetics, the companies said today.


The exclusive agreement, which enables Chemicon to use the targets only for research purposes, covers the BRCA1, BRCA2, p16, p15, and p14 proteins and antibodies. However, the agreement "excludes commercial therapeutic and diagnostic rights and rights to fields of use that Chemicon does not currently serve," the companies said.


BRCA1 and BRCA2 are the two well-recognized cancer-susceptibility genes expressed in breast and ovarian cancers and cell lines, while cyclin-dependent kinase inhibitors p16, p15, and p14 act as tumor suppressor genes. They are known to be frequently deleted or mutated in a wide variety of human tumors.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.